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Background: To compare one-year all-cause and uterine fibroid (UF)-related direct costs in patients treated with
one of the following three uterine-sparing procedures: magnetic resonance-guided focused ultrasound (MRgFUS),
uterine artery embolization (UAE) and myomectomy.
Methods: This retrospective observational cohort study used healthcare claims for several million individuals with
healthcare coverage from employers in the MarketScan Database for the period 2003–2010. UF patients aged 25–54
on their first UF procedure (index) date with 366-day baseline experience, 366-day follow-up period, continuous
health plan enrollment during baseline and follow-up, and absence of any baseline UF procedures were included in
the final sample. Cost outcomes were measured by allowed charges (sum of insurer-paid and patient-paid amounts).
UF-related cost was defined as difference in mean cost between study cohorts and propensity-score-matched control
cohorts without UF. Multivariate adjustment of cost outcomes was conducted using generalized linear models.
Results: The study sample comprised 14,426 patients (MRgFUS = 14; UAE = 4,092; myomectomy = 10,320) with a
higher percent of older patients in MRgFUS cohort (71% vs. 50% vs. 12% in age-group 45–54, P < 0.001). Adjusted
all-cause mean cost was lowest for MRgFUS ($19,763; 95% CI: $10,425-$38,694) followed by myomectomy ($20,407;
95% CI: $19,483-$21,381) and UAE ($25,019; 95% CI: $23,738-$26,376) but without statistical significance. Adjusted
UF-related costs were also not significantly different between the three procedures.
Conclusions: Adjusted all-cause and UF-related costs at one year were not significantly different between patients
undergoing MRgFUS, myomectomy and UAE.
Keywords: Healthcare costs, Myomectomy, Uterine artery embolization (UAE), Uterine fibroids, Magnetic
resonance-guided focused ultrasound (MRgFUS)Introduction
Uterine fibroids (UF) are benign clonal tumors affecting
more than one-fifth of all women of reproductive age
in the U.S [1,2]. Although benign, UF often occur with
severe symptoms including pelvic pain, prolonged periods
with heavy bleeding, bladder pressure, and adverse repro-
ductive outcomes [3-5].
UF-related morbidity has significant economic impli-
cations with direct costs ranging from $5,395 to $9,610
(in adjusted 2010 U.S. Dollars) [1,6,7]. In addition, indirect
costs of UF (e.g., missed work) are significantly higher at
$12,930 versus $8,893 for controls (also adjusted to 2010
values) [6,7]. The overall economic burden of UF in the* Correspondence: borah.bijan@mayo.edu
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(in 2010 U.S. Dollars) annually.
Among the available alternatives to hysterectomy for
UF are endoscopic and abdominal myomectomy, uterine
artery embolization (UAE) and magnetic resonance-guided
focused ultrasound (MRgFUS). Several studies have
assessed the clinical and patient-related outcomes between
these three procedures [8-14]. However, as documented in
a recent Agency for Healthcare Research and Quality pub-
lication, critical gaps exist with regard to relative costs of
available treatment options for UF including MRgFUS,
UAE and myomectomy [3]. Comparison of costs of
MRgFUS, the newest of these options, is complicated by
the fact that major U.S. commercial insurance carriers do
not generally include MRgFUS as a covered UF treatment
option which in turn results in dearth of cost data fortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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as used in this study may circumvent the issue of lack
of cost data for MRgFUS, and provide the best possible
evidence on cost comparison between the three competing
UF treatment procedures. As such, this study aims to
compare both (i) all-cause direct healthcare costs and
(ii) UF-related direct healthcare costs between MRgFUS,
UAE and myomectomy cohorts one year following treat-
ment. This study will use reimbursed amounts by commer-
cial payers as healthcare costs, and thus provide real-world
evidence of relative costs between the three uterine-sparing
procedures for UF treatment.
Methods
Study design & data source
The study was a retrospective cohort analysis of healthcare
costs using claims from MarketScan Commercial Claims
and Encounters database, providing enrollment data and
paid medical claims for patients insured primarily through
large self-insured employers. MarketScan database contains
inpatient and outpatient healthcare utilization, and out-
patient prescription drug experience of several million
employees and their dependents (annually), covered under
a variety of fee-for-service and capitated health plans, in-
cluding exclusive provider organizations, preferred provider
organizations (PPOs), point of service (POS) plans, indem-
nity plans, and health maintenance organizations (HMOs).
MarketScan database also provides detailed cost and out-
comes data associated with healthcare service and drug
utilization described above. This is facilitated by linking
medical claims for each patient to person-level enrollment
data and to outpatient prescription drug claims through
the use of unique enrollee identifiers.
Study population and cohorts
UF patients aged 25–54 years as of their first UF procedure
date (index date) between 2003 and 2010 were used in the
study. Since MRgFUS was approved by FDA in 2004 and
UAE and myomectomy were approved much earlier than
that, we considered all patients who had a UF procedure
between 2004 and 2009. Since we required each patient to
have 1-year baseline and 1-year follow-up, the possible date
range for included claims was 2003 through 2010. Similar
to Carls et al [18]. and as shown in Figure 1, healthcare
costs were assessed for a 1-year baseline period, and for
each of the following segments of the 1-year operative
period: pre-operative (14 days prior to the index date), peri-
operative (from the index date until discharge) and post-
operative (from the discharge date until 1 year after the start
of the pre-operative period). The three study cohorts were
defined based on the index UF procedure: MRgFUS, UAE
and myomectomy (see Table 1 for relevant CPTcodes).
In addition, patients included in the study must have: a
UF diagnosis during the baseline period (see Table 2 forICD-9 diagnosis codes); continuous enrollment in the
health plan during the baseline and follow-up periods; and
absence of any UF treatment procedure during baseline
(see Table 1 for relevant codes).
Patient characteristics
Patient characteristics included index age reported in three
age categories (25–34, 35–44 and 45–54), geographic re-
gion of residence of the primary enrollee (e.g. employee),
whether the patient was the primary enrollee or the spouse
or other dependent, year of the index date, and type of
health plan. Baseline health status was measured using
the Charlson Comorbidity Index (CCI) [19], a count of
the number of psychiatric diagnostic groupings [20],
and the presence of certain diagnoses during the baseline
period (menstrual disorders, pelvic pain, anemia, inflam-
matory disease, non-inflammatory disease, endometriosis,
pregnancy, urinary problems, constipation or gas, other
disorders of the uterus, genital prolapse, benign neoplasm
of the uterus, infertility and breast cancer). Furthermore,
indicators for any inpatient and emergency room (ER) visits
during baseline were extracted to proxy for potentially
higher baseline risk in those patients and hence the poten-
tial for higher costs in the follow-up period not necessarily
related to UF. Pharmacotherapy use (non-steroidal anti-
inflammatories or NSAIDs, and hormone therapy) during
baseline was also captured. The choice of treatment and
consequent costs may be confounded by patients’ socio-
economic characteristics including income, education and
race. Because these variables are not available in insurance
claims, data on median income, percent of black residents
and percent of residents with college education in the pri-
mary enrollee’s 5-digit ZIP code of residence on index date
were used as proxies based on 2010 census data.
Study outcomes
The primary study outcome was all-cause direct healthcare
cost in 2010 U.S. dollars (inflation adjusted using the GDP
Implicit Price Deflator), which included both insurer-paid
amounts and patient-paid amounts (including copayments
and deductibles) for all the claims generated through
the 1-year follow-up period as has been done in previous
studies [1,18]. All-cause cost was also compared between
the three study cohorts for each of the pre-operative, peri-
operative and 1-year post-operative periods separately.
Another outcome assessed was UF-related direct cost
defined as the difference in mean costs between a study co-
hort and its control cohort that included similar patients
from MarketScan database but without a UF diagnosis. At
a minimum, patients in the control cohorts must satisfy fol-
lowing criteria: at least 12 months enrollment before and
after the index date (randomly assigned date to match the
distribution of index dates among patients with UF), be of
age 25–54 on their index date, and did not have any UF
Figure 1 Study period for women with surgery/procedure for UF treatments. This figure delineates the various study periods, including the
baseline and the follow-up operative period.
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score matching [21,22] was used to construct the com-
parison cohorts for myomectomy and UAE using the all
the variables described in the patient characteristics sec-
tion. However, there were not sufficient degrees of free-
dom to use this approach for the 14 MRgFUS patients.Table 1 CPT codes for identifying index cohorts
Treatment category
The 3 study cohorts
Magnetic Resonance Focused
Ultrasound (MRgFUS)
















*Require a UF diagnosis on the claim with the CPT4 code for all of the Radical Hyste
dx codes 218.xx, 219.xx or 654.1x.Instead, each MRgFUS patient was exactly matched to five
comparison patients using a subset of patient characteris-
tics: age (±5 years), Census region, health plan type, index
year, income, education, race, an indicator for baseline
CCI > 0 (described below) and an indicator for baseline
inpatient admission.CPT-4 codes
0071T, 0072T








58150, 58152, 58200,58953, 58954, 58956
58260,58262, 58263, 58267, 58270, 58275, 58280, 58285, 58290-58294
58550, 58552, 58553, 58554, 58541, 58542, 58543, 58544, 58570,
58571, 58572, 58573, 58578*
58180
58210, 58548 and require UF diagnosis on claim for each of the codes
rectomy and UAE CPT4 codes, plus CPT4 code 58578. UF diagnosis = ICD-9-CM
Table 2 Diagnosis codes for uterine fibroids and related
complications/comorbidities
Diagnoses ICD-9-CM diagnosis codes




Inflammatory diseases 614.xx, 616.xx
Noninflammatory diseases 620.xx, 622.xx
Endometriosis 617.xx
Pregnancy V22.x, V23.x, V27.x, 640.00-677
Urinary problems 788.41, 788.20-788.29, 591.xx, 593.5x
Constipation or gas 564.00, 564.09, 787.3




Benign neoplasm of the
uterus/ovary
220.xx
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Descriptive statistics for baseline characteristics, including
mean and standard deviation (SD) for continuous covari-
ates, and frequency and percent for categorical variables,
are provided for each of the three study cohorts.
Selection of women into each treatment cohort is likely
to be the main source of bias. MRgFUS is not accessible to
many patients since this treatment is considered investiga-
tional by most U.S. insurers. We address potential selection
bias in two ways. First, we describe the characteristics
of women in each sample, including comorbidities and
cost prior to surgery, since comorbidities may influence
treatment choices. Second, we adjust costs to control for
observed differences between patients in each treatment
group through multivariate regression.Figure 2 Patient Selection in the MRgFUS Cohort. This figure shows att
exclusion criterion.Multivariate adjustment of cost outcomes
Costs were regression-adjusted to control for baseline
characteristics of women in each treatment group. This was
implemented using generalized linear modeling (GLM)
framework with a gamma distribution and logarithmic
link [23,24]. Separate GLM models were constructed for
costs in each time period, and included indicators for each
treatment cohort and all patient characteristics described
above as independent variables. Predicted costs from these
regressions are reported for each of the study groups.
Mayo Clinic Institutional Review Board considered this
study as exempt from full review given that study used
already existing deidentified data. The analytic dataset was
created using SAS (version 9.2), while the analyses were
conducted in Stata (version 11).
Results
For the primary analysis, 14,426 patients with uterine-
sparing procedures (MRgFUS = 14; UAE = 4,092 and
myomectomy = 10,320) met study criteria. For the second-
ary analysis of fibroid-related costs, a matched group of
14,482 patients without UF were selected (70 MRgFUS,
4,092 UAE, and 10,320 myomectomy). Given that only
14 of the 48 MRgFUS patients found in the MarketScan
database met all our criteria for length of enrollment, we
provided a flowchart in Figure 2 to document the attrition
of patients due to each inclusion/exclusion criterion. In
addition, Table 3 describes the characteristics of the 48
MRgFUS patients found in the database. The 14 MRgFUS
patients who met study criteria were similar to the original
sample of 48 MRgFUS patients in terms of the baseline
characteristics (see Table 4 and Table 3).
Table 4 compares baseline characteristics of the three
study cohorts. Patients in the three cohorts differed in
their age distribution, with higher percentage of MRgFUS
patients (71%) in the age group 45–54 compared to 50%
and 12% in UAE and myomectomy cohorts, respectively.rition of patients in the MRgFUS cohort due to each inclusion or
Table 3 Description of MRgFUS patients (N = 48) and
procedures in data (N = 54)







Fee for service 2 4.2%
Preferred Provider Organization (PPO) 27 56.3%
Point of Service (POS) 4 8.3%
Health Maintance Organizations (HMO) 9 18.8%
Capitated POS 1 2.1%
Consumer Driven Health Plan (CDHP) 4 8.3%
Unknown 1 2.1%
Sociodemographics of ZIP Code of residence
Median household income
Quintile 1 ($0,$28,280) 2 4.2%
Quintile 2 ($28,281, $33,680) 1 2.1%
Quintile 3 ($33,681, $39,204) 6 12.5%
Quintile 4 ($39,205, $48,749) 14 29.2%
Quintile 5 (≥$48,750) 25 52.1%
% over 25 with college degree
Quintile 1 (0-7%) 1 2.1%
Quintile 2 (8-11%) 0 0.0%
Quintile 3 (12-15%) 10 20.8%
Quintile 4 (16-24%) 11 22.9%
Quintile 5 (≥25%) 26 54.2%
% Black
Quintile 1 (0%) 0 0.0%
Quintile 2 (0.1-0.3%) 2 4.2%
Quintile 3 (0.4-1.3%) 6 12.5%
Quintile 4 (1.4-8.5%) 27 56.3%
Quintile 5 (≥8.6%) 13 27.1%
Employment details
Employee (not spouse or dependent) 35 72.9%
Active fulltime 24 50.0%
Salaried 13 27.1%
MRgFUS procedures (N = 54)





Table 3 Description of MRgFUS patients (N = 48) and









Surgical setting N %
Inpatient 1 1.9%
Outpatient 53 98.1%
Inclusion or exclusion in study sample N %
Met study inclusion criteria 14 25.9%
Excluded from study sample
Had other surgeries coded at index
(multiple procedures)
3 5.6%
Incomplete baseline and/or follow-up 31 57.4%
Not the index procedure (Patient had a
prior surgical treatment for UF)
6 11.1%
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MRgFUS. Although geographic distribution of MRgFUS
patients could not be reported in order to protect privacy,
the corresponding p-value suggests that the three study
cohorts were different with regard to their geographic
distribution. The distribution of employee status (whether
primary beneficiary or dependent) between the study
cohorts also differed with 64% of MRgFUS patients
were employees as opposed to 72% and 78% of UAE
and myomectomy patients, respectively. The three study
cohorts also differed with respect to the distribution of
health plan types and the index year.
The three cohorts were different with regard to the their
ZIP code-level income distribution, with a higher percent-
age of women in the MRgFUS cohort (79%) coming from
areas with income greater than $39,204 compared to 67%
and 65% of the patients in the UAE and myomectomy
cohorts, respectively. The distribution of proportion of
black residents in ZIP code-level regions from which
the study patients came from differed between the three
study cohorts, as did the surgical setting (outpatient versus
inpatient) for the patients in the three cohorts.
Baseline health status, as captured by whether CCI > 0,
differed significantly between cohorts (MRgFUS = 14%,
UAE= 16%, Myomectomy = 13%, p-value < 0.001). However,
other data appeared to suggest that women in the MRgFUS
cohort may have more active or severe UF disease. For ex-
ample, the three study cohorts were different with respect
to their baseline NSAID use (MRgFUS = 36%, UAE =
Table 4 Characteristics of patients treated with MRgFUS, UAE and Myomectomy
Patient characteristics MRgFUS UAE Myomectomy P-Valuea
(N = 14) (N = 4,092) (N = 10,320)
Age
25-34 0.0% 4.0% 33.1%
35-44 28.6% 46.4% 55.3%
45-54 71.4% 49.7% 11.6% 0.000
Region
Northeast NR 13.8% 14.2%
Midwest NR 18.8% 15.0%
South NR 52.4% 54.5%
West NR 14.2% 15.7%
Unknown NR 0.7% 0.6% 0.000
Employment details
Employee (not spouse or dependent) 64.3% 71.7% 77.5% 0.000
Plan type
Fee for service 7.1% 3.9% 3.0%
HMO 28.6% 29.3% 24.4%
Point of Service (POS) 7.1% 13.0% 15.0%
Preferred Provider Organization 57.1% 47.9% 51.7%
Capitated POS 0.0% 2.4% 2.0%
Consumer Driven Health Plan (CDHP) 0.0% 2.1% 2.6% 0.000
Year of index date
2004 0.0% 7.4% 10.8%
2005 7.1% 13.8% 13.4%
2006 14.3% 15.2% 14.4%
2007 28.6% 16.5% 17.1%
2008 21.4% 19.0% 19.5%
2009 21.4% 27.4% 24.2% 0.000
Sociodemographics of ZIP Code of residence
Median household income
Quintile 1 ($0,$28,280) 0.0% 8.3% 9.2%
Quintile 2 ($28,281, $33,680) 7.1% 8.3% 9.5%
Quintile 3 ($33,681, $39,204) 14.3% 16.4% 16.5%
Quintile 4 ($39,205, $48,749) 35.7% 19.2% 21.1%
Quintile 5 (≥$48,750) 42.9% 47.8% 43.7% 0.001
% over 25 with college degree
Quintile 1 (0-7%) 0.0% 0.2% 0.3%
Quintile 2 (8-11%) 0.0% 2.3% 2.6%
Quintile 3 (12-15%) 14.3% 13.5% 13.2%
Quintile 4 (16-24%) 71.4% 29.7% 31.0%
Quintile 5 (≥25%) 14.3% 54.2% 52.9% 0.333
% Black
Quintile 1 (0%) 0.0% 3.7% 3.5%
Quintile 2 (0.1-0.3%) 0.0% 7.3% 7.8%
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Table 4 Characteristics of patients treated with MRgFUS, UAE and Myomectomy (Continued)
Quintile 3 (0.4-1.3%) 28.6% 15.5% 15.6%
Quintile 4 (1.4-8.5%) 14.3% 22.2% 23.6%
Quintile 5 (≥8.6%) 57.1% 51.2% 49.5% 0.050
Surgical setting
Inpatient 0.0% 18.3% 74.6%
Outpatient 100.0% 81.7% 25.4% 0.000
Use of pharmacotherapy during baseline
NSAIDs (non-steroidal anti-inflammatories) 35.7% 27.9% 24.9% 0.001
Hormone therapy 42.9% 31.1% 40.5% 0.000
Healthcare use during baseline
Any inpatient visits 14.3% 5.7% 7.0% 0.010
Any ER visits 50.0% 20.8% 24.4% 0.000
Baseline health status
Avg. Charlson Cormorbidity Index 0.14 0.23 0.17
Charlson Cormorbidity Index >0 14.3% 16.0% 12.8% 0.000
Avg. Number of Psychiatric Diagnostic Groupings 2.57 2.06 2.81
Number of Psychiatric Diagnostic Groupings >1 50.0% 58.5% 76.4% 0.000
Menstrual disorders 64.3% 56.3% 45.9% 0.000
Pelvic pain 42.9% 24.0% 31.3% 0.000
Anemias 7.1% 28.4% 17.9% 0.000
Inflammatory disease 28.6% 14.2% 18.4% 0.000
Noninflammatory disease 7.1% 14.0% 17.6% 0.000
Endometriosis 0.0% 2.2% 5.2% 0.000
Pregnancy 7.1% 2.9% 15.2% 0.000
Urinary problems 0.0% 3.4% 3.7% 0.508
Constipation or gas 7.1% 2.8% 2.9% 0.605
Other disorders of the uterus 14.3% 19.4% 13.3% 0.000
Genital prolapse 0.0% 0.5% 0.6% 0.745
Benign neoplasm of the uterus 0.0% 0.1% 0.5% 0.003
Infertility 0.0% 1.0% 14.8% 0.000
Breast cancer 0.0% 0.6% 0.5% 0.729
a. P-value from chi-square test of significance of difference between the groups
NR = not reportable due to small sample size
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use (MRgFUS = 43%, UAE = 31%, Myomectomy = 41%,
p-value < 0.001), baseline inpatient (IP) visits (MRgFUS =
14%, UAE = 6%, Myomectomy = 7%, p-value = 0.01), and
baseline emergency room (ER) use (MRgFUS= 50%, UAE =
21%, Myomectomy = 24%, p-value < 0.001). Compared to
women in UAE and myomectomy cohorts, women under-
going MRgFUS were also more likely to have menstrual
disorders and pelvic pain but less anemia (all p < 0.01).
Table 4 displays other baseline health conditions that exhib-
ited significant differences between the three cohorts.Treatment costs
Table 5 reports average costs (all-cause) during the study
period for each treatment group, both unadjusted and
regression adjusted. One-year average healthcare costs
for MRgFUS, UAE and myomectomy cohorts were
$17,719, $18,638 and $16,879, respectively, and were
not statistically different. While pre-operative costs
were similar between the three cohorts, peri-operative
costs for MRgFUS ($6,301, 95% CI: $2,572, $10,030)
was significantly lower than for UAE ($11,444, 95% CI:
$11,038, $11,849) and myomectomy ($10,555, 95% CI:
Table 5 Mean Costs for each treatment group for each time period (95% confidence intervals)
MRgFUS UAE Myomectomy
(n = 14) (n = 4,092) (n = 10,320)
Unadjusted costs
Baseline $11,562 $6,377 $6,241
($3,039, $20,085) ($6,107, $6,648) ($6,016, $6,465)
Operative year (pre-, peri- and post-operative costs) $17,719 $18,638 $16,879
($10,068, $25,370) ($17,943, $19,332) ($16,592, $17,167)
Pre-operative $564 $786 $558
($18, $1,110) ($707, $866) ($521, $595)
Peri-operative $6,301 $11,444 $10,555
($2,572, $10,030) ($11,038, $11,849) ($10,389, $10,721)
Post-operative $10,854 $6,408 $5,766
($3,573, $18,136) ($5,924, $6,891) ($5,550, $5,982)
Change in costs from baseline to operative year $6,157 $12,260 $10,638
(−$5,294, $17,608) ($11,565, $12,955) ($10,351, $10,925)
Regression adjusted costs*
Baseline $9,901 $8,048 $6,991
($5,562, $17,628) ($7,673, $8,439) ($6,691, $7,302)
Operative year (pre-, peri- and post-operative costs) $19,763 $25,019 $20,407
($10,425, $38,694) ($23,738, $26,376) ($19,483, $21,381)
Pre-operative $556 $1,040 $629
($19, $6,087) ($779, $1,388) ($485, $815)
Peri-operative $7,626 $16,261 $13,938
($187, $10,829) ($11,799, $22,400) ($10,330, $18,808)
Post-operative $11,581 $7,718 $5,840
($4,360, $30,765) ($7,122, $8,372) ($5,427, $6,279)
Change in costs from baseline to operative year $9,862 $16,971 $13,416
(−$435, $20,159) ($15,636, $18,306) ($12,445, $14,387)
*Adjusted costs employed regression models (generalized linear model with gamma distribution and logarithmic link) to control for baseline differences between
women receiving each treatment. The regression included the following control variables, all measured on the index date or during the 1 year baseline period:
age, region, type of health plan, year of procedure, whether the patient was an employee or dependent, whether or not the employee was active full-time,
whether the employee was salaried, demographics characteristics of the ZIP Code where the patient lived, indicators for any outpatient prescription drug fills of
hormone therapies and NSAIDs, the Deyo Charlson Comorbidity Index, number of psychiatric diagnostic groupings, indicators for comorbidities, and indicators for
any hospital stays and any emergency department visits during the baseline year. Demographics of the ZIP code included quintile of zip code median family
income, quintile of percent black and quintile of percent with a college degree.
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MRgFUS ($10,854, 95% CI: $3,573, $18,136) was
higher than that for UAE ($6,408, 95% CI: $5,924,
$6,891) and for myomectomy ($5,766, 95% CI: $5,550,
$5,982) cohorts. The higher post-operative costs for
the MRgFUS cohort was primarily driven by more out-
patient visits (on average, 6.21 for MRgFUS vs. 5.7 for
UAE and 5.5 for myomectomy) resulting in higher out-
patient services cost for this cohort (on average, $5,784
for MRgFUS vs. $3,800 for UAE and $3,355 for myo-
mectomy). Additionally, 2 of the 14 MRgFUS patients
underwent a second UF procedure during the 1-year
follow-up resulting in inpatient costs of $19,307 and
$32,838, respectively. These costs for just 2 patientsskewed the mean inpatient cost for the entire MRgFUS
cohort by more than double the mean cost of the other
two cohorts (on average, $3,725 for MRgFUS vs.
$1,490 for UAE and $1,206 for myomectomy).
Costs increased from baseline to the operative year the
least for the MRgFUS group ($6,157), compared to the
other treatments ($12,260 for UAE and $10,638 for
myomectomy) although this was not a statistically sig-
nificant difference.
Regression adjustment did not significantly alter the
conclusions from the unadjusted analyses described
above. Average adjusted operative year all-cause costs for
MRgFUS, UAE and myomectomy were $19,763, $25,019
and $20,407, respectively and were not statistically different.
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($7,626) compared to UAE ($16,261) cohort; adjusted
peri-operative cost for MRgFUS cohort was also lower
than that for myomectomy ($13,938), but without statistical
significance. The post-operative average cost was higher
for MRgFUS ($11,581) than UAE ($7,718) and myomec-
tomy ($5,840), although this difference was not statisti-
cally significant.
Table 6 presents average costs (unadjusted and regression
adjusted) for each treatment group and their matched com-
parison during the operative year and shows fibroid-related
costs as the difference between costs of the treated group
and their matched comparison group. Unadjusted uterine
fibroid related costs were highest for the MRgFUS group
($13,653) compared to the UAE ($10,839) and myomec-
tomy ($7,906), although the differences between MRgFUS
and the other two groups were not statistically significant.
After regression adjustment, fibroid-related costs for
MRgFUS ($14,614) were in between fibroid-related costs
for UAE ($16,307) and myomectomy ($11,895) although the
95% confidence intervals for MRgFUS overlapped with
those for the other two procedures, implying non-significant
differences between the costs of the study procedures.
Discussion
We found that one-year all-cause costs for MRgFUS
($19,763), myomectomy ($20,407) and UAE ($25,019)
were not statistically different. Concerns have been
raised about the costs of an image-guided procedure
such as MRgFUS due to the costs of advanced imaging.
Based on the data from this study, this concern does
not appear to be justified.
This study significantly extends the literature on the
comparability of MRgFUS costs compared to other fi-
broid treatments. The prior U.S. study that assessed
cost-effectiveness of MRgFUS compared to other treat-
ment options utilized expert opinions and clinical trial
data yet found MRgFUS second only to hysterectomy in
terms of cost-effectiveness [25]. Another study assessed
cost-effectiveness of MRgFUS from the perspective of U.
K.’s National Health Services [26]. In this system, a treat-
ment strategy starting with MRgFUS at age 39 and follow-
ing them to age 56 appears to be more cost-effective over
a wide variety of assumptions than current practice [26].
Using real-world insurance claims data, our study appears
to confirm prior findings that UF treatment costs are simi-
lar to UAE and myomectomy.
The significantly higher post-operative costs for MRgFUS
seen in this study was initially puzzling given that MRgFUS
is an outpatient procedure. Increased costs for both out-
patient office visits and inpatient costs contribute to these
higher MRgFUS costs. Given that MRgFUS is a relatively
novel procedure, especially during the years of this study, it
is possible that patients in this cohort were seen morefrequently by their providers to monitor UF symptom re-
lief. In addition, the small number of patients in the
MRgFUS cohort magnifies the effect of two subjects go-
ing on to additional UF treatment on post-operative in-
patient costs. Thus, the post-operative costs for MRgFUS
cohort appear to be strongly skewed only by 2 of the
MRgFUS patients, thereby rendering these costs less
representative.
In addition to comparative cost estimates, the three
study cohorts also exhibited some other notable trends.
For example, a higher proportion of older women appeared
to have opted for MRgFUS than the other two alternatives.
More specifically, 71% of the patients aged between 45 and
54 opted for MRgFUS as opposed to 50% and 12% for UAE
and myomectomy in this age group (Table 4). No woman
below the age 34 opted for MRgFUS, which could be
due to the fact that data regarding post-MRgFUS preg-
nancy is limited and provider counseling tends to rec-
ommend the most established option when childbearing
is desired [27]. Furthermore, older age has been found
to be associated with better success rate for MRgFUS,
which might have factored in the decision regarding
treatment options [28].
Although not modeled due to lack of data, the extent
of potential loss in indirect income can be gauged from
the fact that at least 64% of the women in the study worked
with an employer contributing data to the MarketScan
database. The remaining 36% of the women who opted
to be in their spouses’ health plans might have also been
employed elsewhere but the database did not capture
their employment status. (Table 4) Since MRgFUS affords
significantly faster recovery to normal activity [29-31], lost
income due to missed workdays can be significantly lower
for the MRgFUS cohort. Another notable finding was
that significantly higher proportions of women under-
going MRgFUS lived in zip codes with the highest quin-
tile of black residents. Because of the disproportionate
impact of uterine fibroids on Black women, the accept-
ability of MRgFUS to this high-risk group may benefit
from further investigation.
The secondary outcome in our study, UF-related cost
for each treatment group, was estimated using matched
comparison group without fibroids. Unlike the com-
parison groups for myomectomy and UAE, a more lim-
ited set of variables was used to select the comparison
group for MRgFUS due to its small sample size. Specif-
ically, a summary of comorbid conditions instead of
the actual comorbid conditions was used in matching.
This approach could potentially select a healthier com-
parison group for MRgFUS than for myomectomy and
UAE. If so, the UF-related costs for MRgFUS may have
been overestimated.
In the current environment where healthcare cost
containment has become the guiding principle for any
Table 6 Mean annual costs for treatment groups and comparison group, showing calculation of fibroid-related costs (95% confidence intervals)
MRgFUS UAE Myomectomy
Treated Matched comparison Treated Matched comparison Treated Matched comparison
(n = 14) (n = 70) (n = 4,092) (n = 4,092) (n = 10,320) (n = 10,320)
Unadjusted costs
Operative costs (pre-, peri- and post-operative costs
for treated, year after index date in comparison group)
$17,719 $4,066 $18,638 $7,798 $16,879 $8,973
($10,068, $25,370) ($2,376, $5,755) ($17,943, $19,332) ($7,268, $8,328) ($16,592, $17,167) ($8,664, $9,283)
Uterine fibroid related costs in year after surgery
(operative costs treated minus comparison group)
$13,653 $10,839 $7,906
($4,944, $22,362) ($10,358, $11,320) ($7,574, $8,328)
Regression adjusted costs*
Operative costs (pre-, peri- and post-operative costs
for treated, year after index date in comparison group)
$19,763 $5,149 $25,019 $8,712 $20,407 $8,512
($10,425, $38,694) ($3,883, $6,892) ($23,738, $26,376) ($8,290, $9,154) ($19,483, $21,381) ($8,092, $8,952)
Uterine fibroid related costs in year after surgery
(operative costs treated minus comparison group)
$14,614 $16,307 $11,895
($7,469, $21,759) ($12,949, $19,665) ($7,996, $15,794)
*Adjusted costs employed regression models (generalized linear model with gamma distribution and logarithmic link) to control for baseline differences between women receiving each treatment. The regression
included the following control variables, all measured on the index date or during the 1 year baseline period: age, region, type of health plan, year of procedure, whether the patient was an employee or dependent,
whether or not the employee was active full-time, whether the employee was salaried, demographics characteristics of the ZIP Code where the patient lived, indicators for any outpatient prescription drug fills of
hormone therapies and NSAIDs, the Deyo Charlson Comorbidity Index, number of psychiatric diagnostic groupings, indicators for comorbidities, and indicators for any hospital stays and any emergency department
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http://www.jtultrasound.com/content/2/1/7healthcare decision in the U.S., uptake of a new technol-
ogy hinges not only on its superior clinical efficacy and
safety profile but also on its cost-effectiveness compared
to the existing alternatives. Clinical safety and effective-
ness of MRgFUS with regard to symptom relief, fibroid
shrinkage, adverse events and recurrence of symptoms
and/or recourse to subsequent procedures have been
shown in many studies worldwide [8,9,11,12,27,32-36].
However, its cost compared to relatively established al-
ternative procedures for UF treatment, UAE and myo-
mectomy, has not been widely documented. The only
NIH-funded comparative effectiveness trial comparing
clinical and economic outcomes associated with MRgFUS
and UAE will not be available for several years [37]. One
important reason for this dearth of comparative cost
data has been due to the fact that the majority of the UF
patient population is expected to be covered by commercial
health insurance plans but most commercial insurance
health plans in the U.S. consider MRgFUS as an experi-
mental procedure [15-17]. Thus, MRgFUS is either not
covered or it is paid for by some insurance plans only
on a case by case basis. Consequently, it is difficult to
gather reasonably large sample size of MRgFUS patients
with cost data, which is particularly true for single-payer
claims databases. Thus, the small sample size for MRgFUS
cohort in our study is a reflection of the current reimburse-
ment environment, and represents real-world evidence.
The multi-payer database used in this study was per-
haps one of the best data sources available at the time
of initiating the study, which had 48 unique patients
from across the U.S. who underwent MRgFUS. Other
comparable commercial claims databases, including
Comprehensive Health Analytics (A Humana Company)
database and IMS LifeLink Database, had either no
MRgFUS patients or had very small number of unique
MRgFUS patients.
Standard limitations of an observational study apply to
our study as well [38], which we sought to minimize
through appropriate multivariate adjustments. As with
any claims-based studies, our study modeled reimbursed
amounts, which did not take into account different health
plan designs, including deductible and copayment, which
might affect patient’s choice of a specific procedure. Finally,
since insurance claims do not record clinical variables
including fibroid size and symptoms, analysis on the basis
of these key variables was not possible.Conclusions
In summary, this study found that, after adjusting for pa-
tient characteristics, 1-year all-cause and UF-related costs
were not different between patients undergoing MRgFUS,
myomectomy and UAE. Restricting access to MRgFUS to
constrain health care costs does not appear to be justified.More experience with MRgFUS can further refine the cost
estimates that our study found.
Condensation
Regression-adjusted one-year all-cause and uterine fibroid-
related costs are not statistically different between patients
undergoing magnetic resonance-guided focused ultrasound,
myomectomy and uterine artery embolization.
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